Source: Journal of Pharmacy and Pharmaceutical Sciences. Unidades: FOB, FMRP, FM
Subjects: ANTI-INFLAMATÓRIOS NÃO ESTEROIDES, CITOCROMO P-450, ANTICOAGULANTES, AGREGAÇÃO PLAQUETÁRIA
ABNT
FORGERINI, Marcela et al. The role of CYP2C9*2, CYP2C9*3 and VKORC1-1639 variants on the susceptibility of upper gastrointestinal bleeding: a full case-control study. Journal of Pharmacy and Pharmaceutical Sciences, v. 26, 2023Tradução . . Disponível em: https://doi.org/10.3389/jpps.2023.11136. Acesso em: 04 set. 2024.APA
Forgerini, M., Urbano, G., Nadai, T. R. de, Batah, S. S., Fabro, A. T., & Mastroianni, P. de C. (2023). The role of CYP2C9*2, CYP2C9*3 and VKORC1-1639 variants on the susceptibility of upper gastrointestinal bleeding: a full case-control study. Journal of Pharmacy and Pharmaceutical Sciences, 26. doi:10.3389/jpps.2023.11136NLM
Forgerini M, Urbano G, Nadai TR de, Batah SS, Fabro AT, Mastroianni P de C. The role of CYP2C9*2, CYP2C9*3 and VKORC1-1639 variants on the susceptibility of upper gastrointestinal bleeding: a full case-control study [Internet]. Journal of Pharmacy and Pharmaceutical Sciences. 2023 ; 26[citado 2024 set. 04 ] Available from: https://doi.org/10.3389/jpps.2023.11136Vancouver
Forgerini M, Urbano G, Nadai TR de, Batah SS, Fabro AT, Mastroianni P de C. The role of CYP2C9*2, CYP2C9*3 and VKORC1-1639 variants on the susceptibility of upper gastrointestinal bleeding: a full case-control study [Internet]. Journal of Pharmacy and Pharmaceutical Sciences. 2023 ; 26[citado 2024 set. 04 ] Available from: https://doi.org/10.3389/jpps.2023.11136